NCT01700829View on ClinicalTrials.gov

Ketamine in the Treatment of Suicidal Depression

PHASE4CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

January 12, 2017

Study Completion Date

July 31, 2017

Conditions
Major Depressive DisorderSuicidal Ideation
Interventions
DRUG

Ketamine

Single dose of 0.5 mg/kg of ketamine given intravenously (in the vein) over 40 minutes

DRUG

Midazolam

Single dose of 0.02 mg/kg of Midazolam given intravenously (in the vein) over 40 minutes

Trial Locations (1)

10032

Columbia University/New York State Psychiatric Institute, New York

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

New York State Psychiatric Institute

OTHER

NCT01700829 - Ketamine in the Treatment of Suicidal Depression | Biotech Hunter | Biotech Hunter